Illumina, Inc. has announced that it has expanded the rights of use for the HiSeq X Sequencing System to allow customers to perform whole-genome sequencing of non-human species.

The HiSeq X™ Ten, composed of 10 HiSeq X Systems, is the first sequencing platform that breaks the $1000 barrier for a 30x human genome. The HiSeq X Ten System is ideal for population-scale ...

Illumina is riding high off its HiSeq X sequencing systems, meeting increased demand with expanded facilities and ambitious plans for growth. Now, the company is rolling out a service to help labs ...

MedGenome announced that it has purchased the Illumina Hiseq X Ten platform to fuel its genomic research services capability and capacity. MedGenome joins a small number of global players in the ...

The Garvan Institute's Kinghorn Centre for Clinical Genomics in Sydney, Australia, was one of the first three organizations in the world to acquire the Illumina HiSeq X Ten sequencing system.

The HiSeq X Ten is the world's first platform to deliver full coverage human genomes for $1,000, including typical instrument depreciation, DNA extraction, library preparation, and estimated labor.

Since the launch of Illumina’s flagship HiSeq X sequencing platform, the cost for a research-grade whole genome has held steady at around $1,000. The only potential competition on the horizon ...

HiSeq X Ten, a new genome sequencing machine lowers the cost of the sequencing process to $1,000. The new technique could bring about a new revolution in the health industry.

Illumina launches new reagent kits to boost the power and efficiency of the HiSeq X Ten and HiSeq 2500 Sequencing Systems.

Here we present a protocol for community amplicon sequencing on the HiSeq2000 and MiSeq Illumina platforms, and apply that protocol to sequence 24 microbial communities from host-associated and ...

The HiSeq X Ten is the world's first platform to deliver full coverage human genomes for less than $1,000, including typical instrument depreciation, DNA extraction, library preparation, and ...